PPARA and metabolic dysfunction-associated steatotic liver disease: Numerous researches have demonstrated that PPARα negatively affects the proinflammatory and Acute Phase Reaction (APR) signaling pathways, as observed in the Systemic Inflammatory, Atherogenic, and Nonalcoholic Fatty Liver Disease (NASH) models (63–67).